Gastroenterology

Back to articles

New Drugs on the Way for Irritable Bowel Syndrome

KEY POINT

Alosetron (Lotronex—Glaxo Wellcome) is the first in a new class of serotonin antagonists that will begin reaching the U.S. market in late winter. These agents will be indicated for irritable bowel syndrome (IBS), but they will vary in their indications, with some better for patients with diarrhea and others better for patients with constipation.